Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News 9 Meters Biopharma Inc (EM) NMTRQ

Healthcare Industrials Biotechnology Conglomerates
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is... see more

Current News (EXPM:NMTRQ)

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

ACCESS Newswire May 30, 2023

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023

ACCESS Newswire May 15, 2023

9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity

ACCESS Newswire April 5, 2023

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022

ACCESS Newswire March 28, 2023

9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

ACCESS Newswire March 15, 2023

9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

ACCESS Newswire March 14, 2023

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

ACCESS Newswire March 7, 2023

9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference

ACCESS Newswire January 31, 2023

9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

ACCESS Newswire November 29, 2022
View More News ››

Opinion & Analysis (EXPM:NMTRQ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:NMTRQ)

NMTR ....NR after yesrdys close...up a little but....

There's lots of shs O/S It's getting "pumped" Not my style No position
Iseneschal - September 27, 2022

new site with deep DD on NMTR

New site with Deep DD on NMTR: FrugalNorwegian.com - All information on 1 page - Catalyst countdown timer - Several videos to watch...
FrugalNorwegian - May 7, 2021

Double$

Enjoy doubling my original investment. 
Bagofhammers - January 29, 2021

Whats Going On Here?

Is it the Dec 21 PR on the COV19 evaluation of respiratory complications? Killing it afterhours as well.
Bagofhammers - January 5, 2021

LARGE INSIDER BUYING - PH3 DRUG

ADDED
CPPInvestments - December 15, 2020

9 Meters - Phase 3 drug / NMTR

Very large (recent) insider/fund buying
CPPInvestments - December 11, 2020
View more Bullboard ››

Kobrea Exploration Corp.

Kobrea Exploration Corp.

Kobrea Exploration Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. It holds a ...
View More »